Clinical development of a new inactivated hepatitis a vaccine

Vidor, Emmanuel; Fritzell, Bernard; Plotkin, Stanley А.

doi:10.1007/bf01713047

Cited by 47 publications

(5 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This could well have been related to the vaccine as reported by others also. 29,30 Overall, the AEs observed in the present study were minimal, but due to the small sample size of the present study, the chance of detecting any rare AE was low.…”

Section: Discussionmentioning

confidence: 56%

Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A™) in healthy Indian children

Bhave¹,

Ghosh²,

Sapru³

et al. 2013

VDT

View full text Add to dashboard Cite

Introduction:The World Health Organization (WHO) recommends either inactivated or live attenuated vaccine against the hepatitis A virus (HAV) infection in countries with high incidence. Live attenuated vaccines against HAV infection have been developed and used exclusively in the People's Republic of China and have shown promising results. This is the first study conducted outside the People's Republic of China to evaluate the immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A™) in healthy Indian children. Material and methods:This was an open-labeled, 8-week (July 2012 to October 2012), noncomparative, non-randomized, confirmatory study conducted at two centers (Kolkata and Pune) in India. A total of 140 healthy Indian children aged 12 months to 12 years were administered live attenuated hepatitis A vaccine at the two centers. Overall, 137 subjects (female: 66, mean age: 4.09±2.5 years) completed the study. The subjects were vaccinated (subcutaneous over the deltoid muscle of the upper arm) with 0.5 mL of live attenuated H2 strain hepatitis A vaccine. Results: Eight weeks after a single dose of the vaccine, 136 subjects from both the centers developed protective immunoglobulin (IgM) G antibodies $20 mIU/mL. The overall seroconversion rate was 99% (Kolkata: 100%, Pune: 98%). The hematological and biochemical parameters remained within normal limits. All the adverse events were non-serious and mild in severity. Conclusion: Live attenuated H2 strain hepatitis A vaccine is immunogenic and safe in Indian children.

show abstract

Section: Discussionmentioning

confidence: 56%

Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A™) in healthy Indian children

Bhave¹,

Ghosh²,

Sapru³

et al. 2013

VDT

View full text Add to dashboard Cite

show abstract

“…In addition to the example of Israel (23), some regions of Australia, Italy, and Spain have implemented a routine childhood vaccination program (12,20,33); routine vaccination is now recommended throughout the United States (1) and in Argentina (34), where studies have shown that vaccination has both healthcare and economic benefits (32).…”

mentioning

confidence: 99%

Universal vaccination of children against hepatitis a in Chile: a cost-effectiveness study

Quezada¹,

Baron-Papillon²,

Coudeville³

et al. 2008

Rev Panam Salud Publica

View full text Add to dashboard Cite

show abstract

“…The HAV vaccine contains purified and inactivated viruses boosted by an aluminium salt as an adjuvant. Two doses are required in a range of six to eight months [ 33 ]. The vaccine is safe and immunogenic in 97–99% of the cases two weeks after the second dose.…”

Section: Vaccinesmentioning

confidence: 99%

Living with HIV and Getting Vaccinated: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

After 40 years of its appearance, human immunodeficiency virus (HIV) infection remains a leading public health challenge worldwide. Since the introduction of antiretroviral treatment (ART), HIV infection has become a chronic condition, and people living with HIV could have life expectancies close to those of the general population. People with HIV often have an increased risk of infection or experience more severe morbidity following exposure to vaccine-preventable diseases. Nowadays, several vaccines are available against bacteria and viruses. However, national and international vaccination guidelines for people with HIV are heterogeneous, and not every vaccine is included. For these reasons, we aimed to perform a narrative review about the vaccinations available for adults living with HIV, reporting the most updated studies performed for each vaccine among this population. We performed a comprehensive literature search through electronic databases (Pubmed—MEDLINE and Embase) and search engines (Google Scholar). We included English peer-reviewed publications (articles and reviews) on HIV and vaccination. Despite widespread use and guideline recommendations, few vaccine trials have been conducted in people with HIV. In addition, not all vaccines are recommended for people with HIV, especially for those with low CD4 cells count. Clinicians should carefully collect the history of vaccinations and patients’ acceptance and preferences and regularly check the presence of antibodies for vaccine-preventable pathogens.

show abstract

Clinical development of a new inactivated hepatitis a vaccine

Cited by 47 publications

References 139 publications

Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A™) in healthy Indian children

Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A™) in healthy Indian children

Universal vaccination of children against hepatitis a in Chile: a cost-effectiveness study

Living with HIV and Getting Vaccinated: A Narrative Review

Contact Info

Product

Resources

About

Clinical development of a new inactivated hepatitis a vaccine

Cited by 47 publications

References 139 publications

Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A&trade;) in healthy Indian children

Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A&trade;) in healthy Indian children

Universal vaccination of children against hepatitis a in Chile: a cost-effectiveness study

Living with HIV and Getting Vaccinated: A Narrative Review

Contact Info

Product

Resources

About

Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A™) in healthy Indian children

Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A™) in healthy Indian children